Allogene Therapeutics, Inc. (ALLO) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Allogene (ALLO) Q1 2026: $200M Capital Raise Extends Runway, Alpha-3 MRD Clearance Hits 58%
  May 14, 2026
• Allogene (ALLO) Q4 2025: Cash Runway Extended Into 2028 as Alpha-3 and Allo329 Enter Proof Phase
  March 13, 2026
• Allogene (ALLO) Q3 2025: Cash Runway Extends to 2027 as Alpha-3 and Allo329 Approach Defining Milestones
  November 07, 2025
• Allogene (ALLO) Q2 2025: Cash Runway Extends to 2027 as Alpha-3 Streamlined for Patient Safety
  August 14, 2025
• Allogene (ALLO) Q1 2025: Cash Runway Extended to 2027 as Alpha-3 Trial Consents Double
  July 06, 2025
• Allogene Therapeutics (ALLO) Q3 2024: 50% Response Rate in RCC Cohort Signals Off-the-Shelf CAR-T Expansion
  November 07, 2024
• Allogene (ALLO) Q2 2024: $445M Cash Extends Runway as Alpha-3 CAR-T Sites Expand
  August 07, 2024
• Allogene (ALLO) Q1 2024: $110M Raise Extends Runway, EU Rights Expand Semicel Market 50%
  May 13, 2024
• Allogene (ALLO) Q4 2023: $3B Alpha-3 LBCL Opportunity Anchors Strategic Pivot to Frontline and Autoimmune Expansion
  March 14, 2024

Browse all companies